fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Nortriptyline

All products: general benefit

Aventyl · DIN 00015237 · 25 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Aventyl · DIN 00015237 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-01-10 · brand AVENTYL · ATC N06AA10 NORTRIPTYLINE · form Capsule · route Oral · ingredients NORTRIPTYLINE (NORTRIPTYLINE HYDROCHLORIDE) 25 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Aventyl: Formulary list price $0.61 per unit (the source does not state the unit; exact figure $0.6054). What the ministry pays, not the patient.

Ministry pays: $0.6054 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00015237)

Source record
DIN 00015237: Aventyl Raw flags: sec3=Y Item: 281604015; group id 466; item number 1174; lccId None; manufacturer id AAP Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.6054; ministry $0.6054 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00015237 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16
Shortage status: active shortage (reported September 15, 2026, estimated to end October 9, 2026, last updated September 19, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00015237
Shortage record checked October 6, 2026

Other products in the same Health Canada class (N06AA): coverage varies; not interchangeable

  • Amitriptyline (Elavil): general benefit
  • Clomipramine (Anafranil Tab): general benefit
  • Desipramine (Pertofrane): general benefit, not a benefit
  • Doxepin (Sinequan): general benefit, not a benefit
  • Imipramine (Tofranil): general benefit, not a benefit
  • Trimipramine (Surmontil): general benefit, not a benefit

17 more in the class list below

Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

TRIMIPRAMINE

· 10 products · Listed, not a benefit (5), General benefit (5) · strengths: 75mg, 12.5mg, 25mg, 50mg, 100mg · Cap, Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

DULOXETINE

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 30mg, 60mg · DR Cap

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATION AVENTYL (nortriptyline hydrochloride) is indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states. 1.1 Pediatrics Pediatrics (< 18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of AVENTYL in pediatric patients has not been established. Therefore, Health Canada has not authorized an indication for pediatric use (see 4.2. Recommended Dose and Dosage Adjustment; 7.1.3. Pediatrics). 1.2 Geriatrics Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 4.2. Recommended Dose and Dosage Adjustment; 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00071859.PDF PM date: JUL 21, 2023 Source product: AVENTYL; DIN 00015229; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Aventyl · DIN 00015237 Shortage status: active shortage (reported 2026-09-15, estimated to end 2026-10-09, last updated 2026-09-19); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00015237

Check this DIN again